PMID- 33611890
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 101
IP  - 6
DP  - 2021 Feb 9
TI  - [A retrospective evaluation of clinicalopathologic characteristics and prognostic 
      factors for synchronous bilateral breast cancer in a single center].
PG  - 410-415
LID - 10.3760/cma.j.cn112137-20201010-02793 [doi]
AB  - Objective: To investigate the clinicopathologic features of synchronous bilateral 
      breast cancer (SBBC) and prognostic factors. Methods: The clinicopathologic 
      features of patients with SBBC treated in Peking University First Hospital from 
      January 2008 to March 2019 were retrospectively analyzed. Results: Of all 4 111 
      patients diagnosed with breast cancer, 57(1.4%) cases were diagnosed with 
      SBBC.Forty-three (75.4%) patients were treated with bilateral mastectomy. The 
      median follow-up time was 58 months. The 5-year disease-free survival of SBBC was 
      80.7% and 5-year overall survival was 84.1%. The N stage and HER2 status of 
      second primary breast cancer were associated with prognosis by univariated 
      analysis (Z=5.866 and 4.231, both P<0.05). Conclusion: Majority of patients with 
      SBBC were treated with bilateral mastectomy. While therapeutic strategy of SBBC 
      should take both tumor burden and biomarker status of bilateral breast cancer 
      into consideration.
FAU - Xin, L
AU  - Xin L
AD  - Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
FAU - Xiang, H Y
AU  - Xiang HY
AD  - Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
FAU - Liu, Y H
AU  - Liu YH
AD  - Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
LA  - chi
GR  - 20180502/Youth Cultivation Fund of Beijing Medical Award Foundation/
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
SB  - IM
MH  - *Breast Neoplasms/pathology
MH  - Disease-Free Survival
MH  - Humans
MH  - Mastectomy
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
EDAT- 2021/02/23 06:00
MHDA- 2021/02/24 06:00
CRDT- 2021/02/22 03:41
PHST- 2021/02/22 03:41 [entrez]
PHST- 2021/02/23 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
AID - 10.3760/cma.j.cn112137-20201010-02793 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2021 Feb 9;101(6):410-415. doi: 
      10.3760/cma.j.cn112137-20201010-02793.